CLINICAL PHARMACOKINETICS

Scope & Guideline

Exploring Clinical Insights in Pharmacokinetics

Introduction

Welcome to your portal for understanding CLINICAL PHARMACOKINETICS, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0312-5963
PublisherADIS INT LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1976 to 2024
AbbreviationCLIN PHARMACOKINET / Clin. Pharmacokinet.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND

Aims and Scopes

Clinical Pharmacokinetics focuses on the study of drug absorption, distribution, metabolism, and excretion (ADME) in clinical settings, emphasizing the application of pharmacokinetic principles to optimize drug therapy in various patient populations.
  1. Population Pharmacokinetics and Pharmacodynamics:
    The journal extensively covers population pharmacokinetics, emphasizing the importance of understanding how drugs behave in diverse populations, including pediatric, geriatric, and those with varying comorbidities.
  2. Pharmacometric Modeling:
    A significant focus is on the application of pharmacometric modeling techniques, such as physiologically-based pharmacokinetic (PBPK) modeling, to predict drug behavior and inform dosing regimens.
  3. Therapeutic Drug Monitoring (TDM):
    The journal frequently addresses the role of TDM in optimizing drug therapies, particularly in populations with altered pharmacokinetics, such as those with renal or hepatic impairments.
  4. Drug-Drug Interactions:
    Research on potential drug-drug interactions and their clinical implications is a core area, helping clinicians understand how concurrent medications can affect pharmacokinetic profiles.
  5. Precision Medicine:
    The journal emphasizes the integration of pharmacogenetics and pharmacogenomics in precision medicine, aiming to tailor drug therapies based on individual genetic profiles and metabolic capacities.
Clinical Pharmacokinetics is witnessing exciting trends and emerging themes that reflect advancements in technology and evolving clinical practices. These trends are shaping the future direction of research and clinical application in pharmacokinetics.
  1. Machine Learning and Artificial Intelligence Applications:
    There is a growing trend in utilizing machine learning and artificial intelligence for predictive modeling and dosage optimization, aiming to enhance individualized patient care.
  2. Physiologically-Based Pharmacokinetic Modeling:
    Increasing emphasis is placed on physiologically-based pharmacokinetic (PBPK) modeling, which allows for more accurate predictions of drug behavior in various populations, including special populations such as pediatrics, geriatrics, and those with comorbidities.
  3. Focus on Special Populations:
    Emerging research is increasingly targeting pharmacokinetics in special populations, including pregnant women, neonates, and patients with specific diseases, reflecting a need for tailored therapeutic approaches.
  4. Integration of Pharmacogenomics:
    There is a notable trend towards integrating pharmacogenomic data into clinical pharmacokinetics, facilitating personalized medicine and improved therapeutic outcomes.
  5. Real-World Evidence and Clinical Applications:
    The journal is seeing more studies that leverage real-world evidence to inform pharmacokinetic modeling and dosing strategies, bridging the gap between research and clinical practice.

Declining or Waning

While Clinical Pharmacokinetics continues to explore a broad range of topics, certain themes have shown a decline in publication frequency or focus over recent years. These waning areas may reflect shifts in research priorities or emerging trends in the field.
  1. Basic Pharmacokinetic Studies:
    There has been a noticeable decline in the publication of basic pharmacokinetic studies that do not directly translate to clinical applications or patient management.
  2. Traditional Drug Interaction Studies:
    Research focusing solely on traditional drug-drug interaction studies without the incorporation of advanced modeling or real-world data has decreased, as the field moves toward more integrated and comprehensive approaches.
  3. Single Drug Studies:
    There is a waning interest in studies examining the pharmacokinetics of single drugs in isolation, with a shift towards evaluating drugs in combination therapies and their interactions.

Similar Journals

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Empowering Researchers to Transform Pharmaceutical Practices
Publisher: ELSEVIERISSN: 0928-0987Frequency: 15 issues/year

The European Journal of Pharmaceutical Sciences is a prestigious academic journal dedicated to advancing the field of pharmaceutical science. Published by Elsevier, the journal boasts an impressive impact factor and is categorized in the Q1 quartile for pharmaceutical science as of 2023, signifying its influence and reputation within the academic community. With a Scopus ranking of #20 out of 183 in the fields of pharmacology, toxicology, and pharmaceutics, the journal provides a vital platform for researchers and practitioners to disseminate innovative studies and groundbreaking research that push the boundaries of drug development and delivery. Based in the Netherlands and operating since 1993, the journal seeks to cover a broad scope of topics related to pharmaceutical sciences, encouraging rigorous evaluations and discussions that enhance the understanding and application of this critical field. The absence of open access underscores the commitment to maintaining high scholarly standards, while still offering avenues for libraries and institutions to provide access to cutting-edge research. As the journal converges towards its 2024 milestones, it continuously aims to foster a vibrant exchange of knowledge among its diverse readership, comprising committed researchers, professionals, and students.

DRUGS IN R&D

Leading the charge in pharmacology and toxicology advancements.
Publisher: SPRINGER INT PUBL AGISSN: 1174-5886Frequency: 4 issues/year

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Unveiling the science behind effective therapeutics.
Publisher: DUSTRI-VERLAG DR KARL FEISTLEISSN: 0946-1965Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.

DRUG METABOLISM REVIEWS

Connecting scholars to the forefront of drug science.
Publisher: TAYLOR & FRANCIS LTDISSN: 0360-2532Frequency: 4 issues/year

Drug Metabolism Reviews is a premier journal dedicated to the dissemination of scientific research and reviews in the field of pharmacology, toxicology, and pharmaceutics, published by Taylor & Francis Ltd. With its inception dating back to 1972, this journal has consistently provided an authoritative platform for scholars and professionals from diverse disciplines to explore the intricate mechanisms of drug metabolism and their implications for therapeutic applications. The journal enjoys commendable rankings, placing in the Q2 quartile for Pharmacology (medical) and the Q1 quartile in the miscellaneous subfield, signaling its significant impact within the community. Notably, it is recognized within the top 96th percentile in General Pharmacology, Toxicology and Pharmaceutics, affirming its esteemed position among academic publications. Although it operates under a subscription model, Drug Metabolism Reviews remains an essential resource for researchers, professionals, and students seeking to deepen their understanding of drug interactions, safety, and efficacy. The insights shared within its pages contribute vital knowledge to the global discourse on drug development and personalized medicine.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Exploring Innovations in Drug Action and Safety
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

BIOPHARMACEUTICS & DRUG DISPOSITION

Empowering Discoveries in Biopharmaceutics
Publisher: WILEYISSN: 0142-2782Frequency: 6 issues/year

BIOPHARMACEUTICS & DRUG DISPOSITION, published by WILEY, is a prominent journal in the fields of biopharmaceutics and pharmacology, dedicated to the dissemination of vital research that spans from the foundational aspects of drug disposition to advanced therapeutic developments. Since its inception in 1979, this journal has established itself as a crucial resource for a diverse audience, including researchers, professionals, and students. With its impact factor indicating solid performance and a current ranking in Q2 for Pharmaceutical Science and Q3 across miscellaneous medicine categories, BIOPHARMACEUTICS & DRUG DISPOSITION serves as a nexus for innovative studies and breakthrough findings. The journal's comprehensive scope ensures that rigorous scientific inquiry is represented, helping to advance the understanding of drug behavior in biological systems. Participating in this scholarly dialogue not only enhances individual knowledge but contributes to the broader pharmaceutical and medical communities, making it an essential publication for all stakeholders interested in drug development and utilization.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Leading the way in pharmacology and therapeutics excellence.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

XENOBIOTICA

Pioneering Research in Pharmacology and Toxicology.
Publisher: TAYLOR & FRANCIS LTDISSN: 0049-8254Frequency: 12 issues/year

XENOBIOTICA is a premier journal in the field of pharmacology and toxicology, published by Taylor & Francis Ltd. With an ISSN of 0049-8254 and E-ISSN 1366-5928, this journal has been at the forefront of research since 1971, providing critical insights and advancements up until 2024. It is recognized for its rigorous peer-reviewed content, occupying a third quartile ranking across various categories including Biochemistry, Health, Toxicology, and Pharmacology as of 2023. The journal serves as a pivotal platform for disseminating innovative findings that address the impact of xenobiotics on health and the environment, making it an essential resource for researchers, professionals, and students engaged in these multidisciplinary fields. While it does not currently offer open access, it is widely respected for its contribution to science, evidenced by its Scopus rankings across different areas of study. The journal encourages submissions that push the boundaries of knowledge and transform our understanding of the effects of chemical substances on living organisms.

AAPS Journal

Transforming Insights into Impactful Pharmaceutical Discoveries.
Publisher: SPRINGERISSN: 1550-7416Frequency: 1 issue/year

AAPS Journal, published by Springer in the United States, is a leading peer-reviewed journal dedicated to the advancement of research in the field of Pharmaceutical Sciences. With an impressive Q1 rank in its category and a position within the 81st percentile of Scopus rankings, it serves as a vital resource for researchers and professionals seeking to disseminate impactful findings and innovative methodologies. The journal publishes high-quality original research, review articles, and technical reports aimed at addressing the multifaceted challenges in pharmacology, toxicology, and pharmaceutics. Operating under an Open Access model, AAPS Journal ensures broad dissemination of knowledge, contributing to the enhanced visibility and accessibility of research outputs. With a publication window spanning from 1999 to 2024, it continues to shape the future of pharmaceutical research and its applications. Researchers, students, and industry professionals will find a valuable repository of cutting-edge knowledge in this esteemed journal.

Current Pharmaceutical Analysis

Exploring the Depths of Pharmaceutical Science
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-4129Frequency: 6 issues/year

Current Pharmaceutical Analysis, published by Bentham Science Publishers Ltd, is a vital resource for professionals and researchers in the fields of Pharmaceutical Science, Biochemistry, and Molecular Medicine. Established in 2006, this peer-reviewed journal aims to provide a platform for the latest advancements and analytical methodologies in pharmaceutical research and drug development. Over the years, it has garnered attention for its rigorous scrutiny and contributions to the landscape of pharmacology, evidenced by its quartile placements in various categories, most notably Q3 in Pharmaceutical Science. Despite its current rankings placing it in the lower quartile in several disciplines, the journal remains an essential venue for both emerging and established researchers seeking to disseminate their findings. With the widespread accessibility of its articles, researchers, professionals, and students can engage with cutting-edge studies to foster innovation in pharmaceutical analysis. For access to the latest research contributions, readers can explore the digital archive and stay updated on pivotal discussions shaping the future of the pharmaceutical sciences.